P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
US-2024400592-A1 · Dec 5, 2024 · US
Chemical compounds
US9873678B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9873678-B2 |
| Application number | US-201515124393-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 17, 2015 |
| Priority date | Mar 18, 2014 |
| Publication date | Jan 23, 2018 |
| Grant date | Jan 23, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound which is: 3,5-diamino-6-chloro-N—((R)-3-((4-((2-(hexyl((2S,3R,4R)-2,3,4,5-tetrahydroxypentyl)amino)ethyl)carbamoyl)benzyl)amino)-2-(2-methylbenzyl)propyl)pyrazine-2-carboxamide: or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition, wherein the composition comprises the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier. 3. A compound which is: 3,5-diamino-6-chloro-N—((R)-3-((4-((2-(hexyl((2S,3R,4R)-2,3,4,5-tetrahydroxypentyl)amino)ethyl)carbamoyl)benzyl)amino)-2-(2-methylbenzyl)propyl)pyrazine-2-carboxamide: 4. A pharmaceutical composition, wherein the composition comprises the compound according to claim 3 , and a pharmaceutically acceptable adjuvant, diluent or carrier.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
for electrolyte homeostasis · CPC title
Drugs for disorders of the respiratory system · CPC title
containing three or more hetero rings · CPC title
- C07D401/06Primary
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9873678B2 cover?
- The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
- Who is the assignee on this patent?
- Astrazeneca Ab
- What technology area does this patent fall under?
- Primary CPC classification C07D401/06. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).